Effectively, clinical trials phase I in patients with chronic obstructive pulmonary disease (COPD) confirmed the safety of MSCs; outcomes from phase I/II clinical trial administration and investigation showed their potential anti-inflammatory effects, reporting a reduction in C-reactive protein levels [52]. This evidence concerns the gene CRP and chronic obstructive pulmonary disease.